儿童耐药性癫痫饮食疗法的疗效与安全性:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入12项随机临床试验共907例儿童耐药性癫痫患者,比较生酮饮食、改良Atkins饮食与低血糖指数疗法。短期结果显示所有饮食疗法在癫痫发作减少50%及以上方面均优于常规照护,但生酮饮食与改良Atkins饮食因不良事件停药率显著高于常规照护,各饮食疗法间疗效与安全性无显著差异。
要点
- 所有饮食疗法短期减少癫痫发作≥50%均优于常规照护
- 生酮饮食与改良Atkins饮食因不良事件停药率显著高于常规照护
- 各饮食疗法间疗效与安全性间接比较无显著差异
核心结论
- 儿童耐药性癫痫中所有饮食疗法短期均有效,但生酮饮食与改良Atkins饮食不良事件相关停药率显著高于常规照护,各饮食疗法间疗效与安全性无显著差异。
研究设计与样本
- 系统综述与网状Meta分析(频率学派),检索PubMed、Embase、Cochrane和Ovid自建库至2022年4月的随机临床试验。
- 纳入比较生酮饮食、改良Atkins饮食、低血糖指数疗法彼此之间或与常规照护的随机临床试验,共12项试验907例患者。
- 采用Cochrane偏倚风险工具评估研究质量,随机效应模型计算比值比(OR)及95%CI,用累积排序曲线下面积定义干预排序。
主要发现
- 短期减少癫痫发作≥50%方面,所有饮食疗法均优于常规照护:低血糖指数疗法OR 24.7(95%CI 5.3-115.4),改良Atkins饮食OR 11.3(95%CI 5.1-25.1),生酮饮食OR 8.6(95%CI 3.7-20.0)。
- 短期减少癫痫发作≥90%方面,生酮饮食OR 6.5(95%CI 2.3-18.0)与改良Atkins饮食OR 5.1(95%CI 2.2-12.0)优于常规照护。
- 不良事件相关停药率方面,生酮饮食OR 8.6(95%CI 1.8-40.6)与改良Atkins饮食OR 6.5(95%CI 1.4-31.2)显著高于常规照护。
- 间接比较显示各饮食疗法间疗效与安全性结局无显著差异。
关键数值与推荐
- 主要疗效结局为短期(≤3个月)癫痫发作频率减少≥50%和≥90%,主要安全性结局为因不良事件停药。
- 短期减少发作≥50%:低血糖指数疗法OR 24.7(95%CI 5.3-115.4)、改良Atkins饮食OR 11.3(95%CI 5.1-25.1)、生酮饮食OR 8.6(95%CI 3.7-20.0),均优于常规照护。
- 短期减少发作≥90%:生酮饮食OR 6.5(95%CI 2.3-18.0)、改良Atkins饮食OR 5.1(95%CI 2.2-12.0),优于常规照护。
- 不良事件相关停药:生酮饮食OR 8.6(95%CI 1.8-40.6)、改良Atkins饮食OR 6.5(95%CI 1.4-31.2),高于常规照护。
临床怎么用
- 儿童耐药性癫痫可考虑饮食疗法作为短期辅助治疗,所有纳入疗法均优于常规照护。
- 选择生酮饮食或改良Atkins饮食时需权衡疗效与不良事件相关停药风险。
- 改良Atkins饮食耐受性较好、减少发作≥50%概率较高,可能较生酮饮食更合适,但需直接头对头研究确认。
局限性
- 仅纳入短期(≤3个月)结局,缺乏长期疗效与安全性数据。
- 各饮食疗法间比较为间接比较,无显著差异。
- 需直接头对头比较研究确认 findings。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite advances in the understanding of dietary therapies in children with drug-resistant epilepsy, no quantitative comparison exists between different dietary interventions. OBJECTIVE: To evaluate the comparative efficacy and safety of various dietary therapies in childhood drug-resistant epilepsy. DATA SOURCES: Systematic review and network meta-analysis (frequentist) of studies in PubMed, Embase, Cochrane, and Ovid published from inception to April 2022 using the search terms ketogenic diet, medium chain triglyceride diet, modified Atkins diet, low glycemic index therapy, and refractory epilepsy. STUDY SELECTION: Randomized clinical trials comparing different dietary therapies (ketogenic diet, modified Atkins diet, and low glycemic index therapy) with each other or care as usual in childhood drug-resistant epilepsy were included. Abstract, title, and full text were screened independently by 2 reviewers. DATA EXTRACTION AND SYNTHESIS: Data extraction was conducted following Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline. Cochrane risk-of-bias tool was used to assess the study quality. Effect sizes were calculated as odds ratio with 95% CI using random-effects model. The hierarchy of competing interventions was defined using the surface under the cumulative ranking curve. MAIN OUTCOMES AND MEASURES: Short-term (≤3 months) 50% or higher and 90% or higher reduction in seizure frequency and treatment withdrawal due to adverse events were the primary efficacy and safety outcomes. RESULTS: Of 2158 citations, 12 randomized clinical trials (907 patients) qualified for inclusion. In the short term, all dietary interventions were more efficacious than care as usual for 50% or higher seizure reduction (low glycemic index therapy: odds ratio [OR], 24.7 [95% CI, 5.3-115.4]; modified Atkins diet: OR, 11.3 [95% CI, 5.1-25.1]; ketogenic diet: OR, 8.6 [95% CI, 3.7-20.0]), while ketogenic diet (OR, 6.5 [95% CI, 2.3-18.0]) and modified Atkins diet (OR, 5.1 [95% CI, 2.2-12.0]) were better than care as usual for seizure reduction of 90% or higher. However, adverse event-related discontinuation rates were significantly higher for ketogenic diet (OR, 8.6 [95% CI, 1.8-40.6]) and modified Atkins diet (OR, 6.5 [95% CI, 1.4-31.2]) compared with care as usual. Indirectly, there was no significant difference between dietary therapies in efficacy and safety outcomes. CONCLUSIONS AND RELEVANCE: This study found that all dietary therapies are effective in the short term. However, modified Atkins diet had better tolerability, higher probability for 50% or higher seizure reduction, and comparable probability for 90% or higher seizure reduction and may be a sounder option than ketogenic diet. Direct head-to-head comparison studies are needed to confirm these findings.
引用
- Devi N, Madaan P, Kandoth N, et al. Efficacy and Safety of Dietary Therapies for Childhood Drug-Resistant Epilepsy: A Systematic Review and Network Meta-analysis. JAMA Pediatr. 2023. PMID: 36716045. doi:10.1001/jamapediatrics.2022.5648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。